---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-066645"
form_type: "8-K"
ticker: "INBX"
cik: "0002007919"
company_name: "Inhibrx Biosciences, Inc."
filed_at: "2024-05-30T23:59:59+00:00"
generated_at: "2026-06-01T07:30:03.752138+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Inhibrx Biosciences completes spin-off from RemainCo, lists 14.5M shares outstanding

## Summary
- Completed spin-off on May 29, 2024; 92% of Inhibrx Biosciences shares distributed to RemainCo shareholders at 1:4 ratio.
- As of May 30, 2024, 14,475,904 shares of common stock outstanding post-distribution.
- Issued warrants for up to 991,849 shares at $0.0001 exercise price, no expiration; also issued 1,838 shares to Oxford Finance.
- Entered registration rights agreement requiring filing of resale registration statement within 10 business days.
- Entered employment agreements with CEO Lappe ($695,250 base), CFO Eckelman ($535,600), and CAO Deck ($460,100) with 12-month severance.

## SEC filing metadata
- accession: 0001104659-24-066645
- form_type: 8-K
- ticker: INBX
- cik: 0002007919
- company_name: Inhibrx Biosciences, Inc.
- filed_at: 2024-05-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 5.03, 5.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2007919/000110465924066645/0001104659-24-066645-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2007919/000110465924066645/tm243190d19_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-066645
- JSON: https://secwatch.observer/filing/0001104659-24-066645.json
- Plain text: https://secwatch.observer/filing/0001104659-24-066645.txt

## Key facts
- M&A Transactions
  Inhibrx Biosciences, Inc. underwent a change of control involving Inhibrx, Inc. (closed 2024-05-29).
  - Action: change of control
  - Counterparty: Inhibrx, Inc.
  - Closing: 2024-05-29
  source text: On May 29, 2024, Inhibrx, Inc., a Delaware corporation (“RemainCo”), completed the distribution of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc., a Delaware corporation (the “Company”), to holders of shares of RemainCo’s common stock as of the distribution record date of May 17, 2024, on a pro rata basis (the “Distribution”), at a ratio of one share of the Company’s common stock for every four shares of RemainCo’s issued and outstanding common stock held on the distribution record date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2007919/000110465924066645/0001104659-24-066645-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.